Joint Pain Injections Global Market Report 2024

Joint pain injections serve to reduce inflammation and discomfort, typically administered directly into the joint to alleviate pain. Joint pain is a common occurrence, particularly among the elderly or individuals with pre-existing medical conditions or disorders. Conditions such as arthritis, characterized by pain and inflammation, often contribute to joint pain. Joint pain injections offer a non-surgical approach to quickly relieve joint pain and inflammation.

The primary types of injections for joint pain include steroid joint injections, hyaluronic acid injections, platelet-rich plasma (PRP) injections, placental tissue matrix (PTM) injections, and various others. Steroid joint injections, also known as corticosteroid injections, are anti-inflammatory medications used to treat joint pain. They are particularly effective in reducing inflammation in individuals with conditions like rheumatoid arthritis and other forms of inflammatory arthritis. Joint pain injections are applied to various types of joints, including the hip joint, knee and ankle joints, shoulder and elbow joints, facet joints of the spine, and others. These injections are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The joint pain injections market research report is one of a series of new reports that provides joint pain injections market statistics, including joint pain injections industry global market size, regional shares, competitors with a joint pain injections market share, detailed joint pain injections market segments, market trends and opportunities, and any further data you may need to thrive in the joint pain injections industry. This joint pain injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The joint pain injections market size has grown rapidly in recent years. It will grow from $5.19 billion in 2023 to $5.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth observed in the historical period can be attributed to factors such as an increased aging population, a prevalence of arthritis, global health initiatives, the digitalization of healthcare, and a growing awareness of chronic pain management.

The joint pain injections market size is expected to see rapid growth in the next few years. It will grow to $8.8 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The projected growth in the forecast period can be linked to the expansion of telehealth services, the development of personalized pain management approaches, increased focus on patient education and empowerment, the adoption of sustainable healthcare practices, and the integration of nutritional support. Key trends expected in the forecast period involve advancements in regenerative medicine, further developments in personalized pain management, innovation in injection materials, the incorporation of rehabilitation technologies, and the use of artificial intelligence (AI) to enhance injections.

The joint pain injections market is poised for growth due to the increasing prevalence of arthritis and musculoskeletal disorders. Musculoskeletal disorders rank as the leading cause of disability globally, with low back pain standing out as the primary cause of impairment in 160 nations. Patients seek pain relief and address inflammatory conditions through injections. According to a report by the World Health Organization (WHO) in February 2021, approximately 1.71 billion people worldwide are affected by musculoskeletal conditions, a number continually rising due to population growth and aging. Similarly, arthritis, affecting around 350 million people globally and rapidly increasing, contributes to the upward trajectory of the joint pain injections market.

The growth of the joint pain injections market is expected to be propelled by the increase in the incidence of chronic pain. Chronic pain, persisting for an extended period, is a prevalent issue affecting millions globally. Joint pain injections play a crucial role in managing chronic pain, especially when associated with musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, or other joint-related problems. As highlighted by the World Health Organization (WHO) in September 2022, chronic diseases, including those causing chronic pain, account for a significant percentage of global deaths. The escalating incidence of chronic pain is, therefore, a driving force behind the growth of the joint pain injections market.

A prominent trend in the joint pain injections market is the focus on new product development. Major companies in this sector are actively engaged in innovating new products to meet consumer demand and enhance their market position. For instance, Contura International Ltd., a UK-based manufacturer of therapeutic hydrogels, introduced Arthrosamid in September 2021. Arthrosamid, an innovative hydrogel injection for knee osteoarthritis, utilizes non-biodegradable hydrogel technology, providing a potent, long-lasting, secure, and minimally intrusive treatment for knee osteoarthritis pain.

Major companies in the joint pain injections market are introducing new products to augment their market presence. In May 2021, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched JOYCLU 30mg Intra-articular Injection, aimed at improving joint function. The injection is designed for the treatment of knee and hip osteoarthritis, combining hyaluronic acid and the anti-inflammatory medication diclofenac through a patented Seikagaku technique.

In October 2021, Pacira BioSciences, a US-based company specializing in non-opioid pain management, acquired Flexion Therapeutics for $630 million. This acquisition strengthens patient access to Zilretta, Flexion Therapeutics' principal product - a non-opioid injection for pain treatment. Zilretta is the only FDA-approved injection for intra-articular therapy in patients facing osteoarthritis-related knee pain. The acquisition also provides Pacira access to Flexion's medication candidates, FX201 and FX301, further expanding its portfolio in musculoskeletal disorder treatment.

Major companies operating in the joint pain injections market include Seikagaku Corporation, Flexion Therapeutics Inc., Zimmer Biomet Holdings Inc., Sanofi S.A., Anika Therapeutics Inc., Abbvie Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Johnson & Johnson Services Ltd., Merck & Co. Inc., GlaxoSmithKline PLC, Novartis AG, AstraZeneca PLC, Roche Holding AG, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Bayer AG, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen SA, Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Zydus Lifesciences Limited

North America was the largest region in the joint pain injections market in 2023. The regions covered in the joint pain injections market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the joint pain injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The joint pain injections market consists of sales of epidural steroid injections, facet joint injections, viscosupplementation injections, corticosteroid injections and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.